| Name | Title | Contact Details |
|---|
Cognosci is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Confluent Medical Technologies is the leading contract manufacturer of Nitinol-based components, balloon components, and balloon catheters.
For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.
Isto Biologics is an orthobiologics company dedicated to helping patients heal faster through advanced solutions for spine, orthopedics, sports and regenerative medicine.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.